Baseline patient characteristics
| Variable . | Frontline HCVAD based, n = 35 . | Frontline SL-401, n = 37 . | Frontline other treatment, n = 28 . | P . |
|---|---|---|---|---|
| Sex | ||||
| Male | 33 (94) | 27 (73) | 21 (75) | .045 |
| Female | 2 (6) | 10 (27) | 7 (25) | |
| Age at Dx, median (range), y | 61 (20-86) | 68 (21-84) | 65 (14-86) | .035 |
| WBCs at Dx, median, (range), ×109/L | 6.4 (1.7-76.5) | 5.8 (1.9-56.8) | 6.0 (1.5-179) | .85 |
| Hgb at Dx, median (range), g/dL | 13.3 (6.8-17.0) | 13.1 (8.3-17) | 13.0 (7.7-17.1) | .088 |
| Plt at Dx, median (range), ×109/L | 141 (11-365) | 146 (39-407) | 136 (22-260) | .779 |
| LDH, U/L at Dx, median (range), (n = 30) | 508 (121-4108) | 505 (164-1800) | 523 (266-505) | .841 |
| BM Bl at Dx, median (range), % | 5 (0-95) | 14 (0-94 | 11 (0-86) | .788 |
| Involvement of BPDCN disease | ||||
| Bone marrow | 25 (71) | 26 (70) | 21 (75) | .911 |
| Skin | 27 (77) | 34 (92) | 18 (64) | .024 |
| Lymph node | 14 (40) | 6 (16) | 4 (14) | .022 |
| CNS | 7 (20) | 1 (3) | 4 (14) | .07 |
| Cytogenetics | ||||
| Complex cytogenetics | 10 (29) | 6 (16) | 4 (14) | .206 |
| Diploid cytogenetics | 17 (48) | 29 (78) | 17 (61) | |
| Mutations | ||||
| TET2 | 7/13 (54) | 28/35 (80) | 12/13 (92) | .054 |
| ASXL1 | 4/13 (31) | 12/35 (34) | 6/13 (46) | .677 |
| RAS | 2/14 (14) | 4/35 (11) | 9/50 (18) | .004 |
| Frontline therapy | ||||
| HCVAD | 32 (91) | |||
| HCVAD | 23 (66) | |||
| HCVAD + Ven | 4 (11) | |||
| Mini-HCVAD + Ven, with or without enasidenib | 2 (6) | |||
| HCVAD + bortezomib | 2 (6) | |||
| Modified HCVAD | 1 (3) | |||
| HCVAD + SL401, with or without Ven | 3 (9) | |||
| CHOP | 8 (29) | |||
| AML based | 6 (21) | |||
| Bortezomib based | 2 (7) | |||
| Hypomethylator based | 4 (14) | |||
| Other treatment regimens | 8 (29) | |||
| CR | 28 (80) | 22 (59) | 12 (43) | .01 |
| HSCT | 18 (51) | 17 (49) | 10 (36) | .455 |
| Hematopoietic stem cell transplant in CR1 | 15/28 (54) | 13/22 (59) | 4/12 (33) | .297 |
| OS, median, mo | 28.3 | 13.7 | 22.8 | .566 |
| CR1 duration, median, mo | 38.6 | 10.7 | 21.4 | .444 |
| Days to Rx1, median (range) | 27 (0-108) | 32 (0-112) | 28 (0-421) | .187 |
| Males | 27 (0-108) | 32 (11-84) | 39 (0-421) | .268 |
| Females | 46 (28-64) | 36 (0-112) | 30 (5-83) | .195 |
| Dx/Rx1 with skin only | 9 (26) | 15 (41) | 9 (32) | .406 |
| Days to Rx1, median (range) | 40 (8-95) | 36 (7-101) | 28 (0- 421) | .274 |
| Variable . | Frontline HCVAD based, n = 35 . | Frontline SL-401, n = 37 . | Frontline other treatment, n = 28 . | P . |
|---|---|---|---|---|
| Sex | ||||
| Male | 33 (94) | 27 (73) | 21 (75) | .045 |
| Female | 2 (6) | 10 (27) | 7 (25) | |
| Age at Dx, median (range), y | 61 (20-86) | 68 (21-84) | 65 (14-86) | .035 |
| WBCs at Dx, median, (range), ×109/L | 6.4 (1.7-76.5) | 5.8 (1.9-56.8) | 6.0 (1.5-179) | .85 |
| Hgb at Dx, median (range), g/dL | 13.3 (6.8-17.0) | 13.1 (8.3-17) | 13.0 (7.7-17.1) | .088 |
| Plt at Dx, median (range), ×109/L | 141 (11-365) | 146 (39-407) | 136 (22-260) | .779 |
| LDH, U/L at Dx, median (range), (n = 30) | 508 (121-4108) | 505 (164-1800) | 523 (266-505) | .841 |
| BM Bl at Dx, median (range), % | 5 (0-95) | 14 (0-94 | 11 (0-86) | .788 |
| Involvement of BPDCN disease | ||||
| Bone marrow | 25 (71) | 26 (70) | 21 (75) | .911 |
| Skin | 27 (77) | 34 (92) | 18 (64) | .024 |
| Lymph node | 14 (40) | 6 (16) | 4 (14) | .022 |
| CNS | 7 (20) | 1 (3) | 4 (14) | .07 |
| Cytogenetics | ||||
| Complex cytogenetics | 10 (29) | 6 (16) | 4 (14) | .206 |
| Diploid cytogenetics | 17 (48) | 29 (78) | 17 (61) | |
| Mutations | ||||
| TET2 | 7/13 (54) | 28/35 (80) | 12/13 (92) | .054 |
| ASXL1 | 4/13 (31) | 12/35 (34) | 6/13 (46) | .677 |
| RAS | 2/14 (14) | 4/35 (11) | 9/50 (18) | .004 |
| Frontline therapy | ||||
| HCVAD | 32 (91) | |||
| HCVAD | 23 (66) | |||
| HCVAD + Ven | 4 (11) | |||
| Mini-HCVAD + Ven, with or without enasidenib | 2 (6) | |||
| HCVAD + bortezomib | 2 (6) | |||
| Modified HCVAD | 1 (3) | |||
| HCVAD + SL401, with or without Ven | 3 (9) | |||
| CHOP | 8 (29) | |||
| AML based | 6 (21) | |||
| Bortezomib based | 2 (7) | |||
| Hypomethylator based | 4 (14) | |||
| Other treatment regimens | 8 (29) | |||
| CR | 28 (80) | 22 (59) | 12 (43) | .01 |
| HSCT | 18 (51) | 17 (49) | 10 (36) | .455 |
| Hematopoietic stem cell transplant in CR1 | 15/28 (54) | 13/22 (59) | 4/12 (33) | .297 |
| OS, median, mo | 28.3 | 13.7 | 22.8 | .566 |
| CR1 duration, median, mo | 38.6 | 10.7 | 21.4 | .444 |
| Days to Rx1, median (range) | 27 (0-108) | 32 (0-112) | 28 (0-421) | .187 |
| Males | 27 (0-108) | 32 (11-84) | 39 (0-421) | .268 |
| Females | 46 (28-64) | 36 (0-112) | 30 (5-83) | .195 |
| Dx/Rx1 with skin only | 9 (26) | 15 (41) | 9 (32) | .406 |
| Days to Rx1, median (range) | 40 (8-95) | 36 (7-101) | 28 (0- 421) | .274 |
Unless otherwise noted, data are n (%).
BM Bl, bone marrow blast; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; Dx, diagnosis; Hgb, hemoglobin; Plt, platelet; LDH, lactate dehydrogenase; Rx1, first treatment; Ven, venetoclax; WBC, white blood cell.
P values in bold denote statistical significance.